Platinum Sensitivity in IDH1/2 Mutated Intrahepatic Cholangiocarcinoma: Not All "BRCAness" Is Created Equal.

IF 1.8 4区医学 Q3 ONCOLOGY

Cancer Investigation Pub Date : 2023-09-01 DOI:10.1080/07357907.2023.2242957

Deborah Blythe Doroshow, Wei Wei, Meenakshi Mehrotra, Daniella Sia, Joseph Paul Eder, Ranjit Bindra, Jane Houldsworth, Patricia LoRusso, Zenta Walther

引用次数: 0

Abstract

Preclinical data suggest that IDH1/2 mutations result in defective homologous recombination repair (HRR). We hypothesized that patients with IDH1/2mt intrahepatic cholangiocarcinoma (IHCC) would benefit more from 1 L platinum chemotherapy than patients with wildtype (WT) tumors. We performed a multicenter retrospective study of 81 patients with unresectable IHCC treated with 1 L platinum with a primary endpoint of clinical benefit rate (CBR). Patients with IDH1/2mt tumors had a similar CBR and objective response rate compared to those with IDH WT disease (59 versus 54%; p = 0.803), suggesting that a relationship between platinum sensitivity and HRR gene defects may be specific to tumor context.

查看原文本刊更多论文

IDH1/2突变肝内胆管癌的铂敏感性:并非所有的“BRCAness”都是平等的。

临床前数据表明，IDH1/2突变导致同源重组修复(HRR)缺陷。我们假设IDH1/2mt肝内胆管癌(IHCC)患者比野生型(WT)肿瘤患者从1l铂化疗中获益更多。我们对81例不可切除的IHCC患者进行了一项多中心回顾性研究，以临床获益率(CBR)为主要终点，采用1l铂治疗。与IDH WT患者相比，IDH1/2mt肿瘤患者具有相似的CBR和客观缓解率(59%对54%;p = 0.803)，提示铂敏感性与HRR基因缺陷之间的关系可能与肿瘤环境有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Investigation 医学-肿瘤学

CiteScore

3.80

自引率

4.20%

发文量

审稿时长

8.5 months

期刊介绍： Cancer Investigation is one of the most highly regarded and recognized journals in the field of basic and clinical oncology. It is designed to give physicians a comprehensive resource on the current state of progress in the cancer field as well as a broad background of reliable information necessary for effective decision making. In addition to presenting original papers of fundamental significance, it also publishes reviews, essays, specialized presentations of controversies, considerations of new technologies and their applications to specific laboratory problems, discussions of public issues, miniseries on major topics, new and experimental drugs and therapies, and an innovative letters to the editor section. One of the unique features of the journal is its departmentalized editorial sections reporting on more than 30 subject categories covering the broad spectrum of specialized areas that together comprise the field of oncology. Edited by leading physicians and research scientists, these sections make Cancer Investigation the prime resource for clinicians seeking to make sense of the sometimes-overwhelming amount of information available throughout the field. In addition to its peer-reviewed clinical research, the journal also features translational studies that bridge the gap between the laboratory and the clinic.